Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsBiotechnology Equipment

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1524082

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1524082

Molecular Diagnostics Market Size, Share & Trends by Product & Services, Test Type, Sample, Technology, Application (Infectious, Oncology) - Global Forecast to 2029

PUBLISHED:
PAGES: 447 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The molecular diagnostics market is valued at an estimated USD 17.3 billion in 2024 and is projected to reach USD 32.7 billion by 2029 at a CAGR of 13.5% during the forecast period. Molecular diagnostics is a powerful tool for detecting diseases early by examining them at the genetic and molecular level. These advanced techniques can find pathogens very precisely and with high sensitivity. Early diagnosis is crucial because it lets treatment begin sooner, which can prevent the spread of the disease, lessen complications, and improve overall patient health. Moreover, in countries like India, both government and private initiatives are playing a significant role in enhancing public awareness and ensuring greater accessibility to diagnostic and treatment services. Such initiatives are expected to increase the use of molecular diagnostics in the coming years.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD Billion)
SegmentsBy Product & service, test type, sample type, technology, application, and end user
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries

"DNA sequencing & next-generation sequencing (NGS) segment accounted for the highest growth rate in the molecular diagnostics market, by technology, during the forecast period."

Based on technology, the molecular diagnostics market is bifurcated into polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies. The DNA sequencing & NGS segment in the molecular diagnostics market is experiencing substantial growth. This technology has been rapidly improving, with faster, more accurate, and more affordable ways to sequence DNA. Advancements like high-speed sequencers and better methods for processing DNA samples and data analysis are making these technologies easier to use and more effective.

"Diagnostic laboratories segment is expected to have the fastest growth rate in the molecular diagnostics market, by end user, during the forecast period."

The molecular diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, and other end users, based on end user. Diagnostic laboratories segment is expected to account for the highest CAGR during the forecast period. This growth can be attributed to factors like the increasing volume of tests for infectious diseases and cancer that necessitates efficient and accurate solutions, increasing investments in healthcare infrastructure, and the presence of the specialized expertise required for complex molecular testing that are prompting healthcare providers to outsource these procedures to diagnostic laboratories.

"Asia Pacific: The fastest-growing region in molecular diagnostics market."

The worldwide market for molecular diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. Notably, the Asia Pacific region is anticipated to experience the most substantial growth in the forecast period. The Asia Pacific region, a hub for medical tourism, is rapidly emerging as a leader in the market for medical procedures and devices. Furthermore, healthcare spending in Asia Pacific is on the rise, indicating a growing demand for advanced medical services. This demand is being met by the rapid expansion of medical infrastructure, particularly in countries like India and China, where the number of hospitals and diagnostic laboratories is experiencing significant growth. Additionally, countries like India, China, and Japan are making substantial investments in research dedicated to developing innovative diagnostic procedures. This confluence of factors is propelling the molecular diagnostics market within the Asia Pacific region.

The break-up of the profile of primary participants in the molecular diagnostics market:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in this market are Danaher (US), F. Hoffmann-La Roche Ltd. (Switzerland), Illumina, Inc. (US), bioMerieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Exact Sciences Corporation (US), Genetic Signatures (Australia), Agilent Technologies, Inc. (US), MDxHealth (Belgium), Biocartis (Belgium), TBG Diagnostics Limited (Australia), HTG Molecular Diagnostics, Inc. (US), Vela Diagnostics (Singapore), Amoy Diagnostics Co., Ltd. (China), ELITechGroup (France), Molbio Diagnostics Pvt. Ltd. (India), geneOmbio Technologies (India), Savyon Diagnostics (Israel), and Uniogen OY (Finland).

Research Coverage:

This research report categorizes the molecular diagnostics market by product & service (reagents & kits, instruments, and services), by test type (lab tests and PoC tests), by sample type (blood, serum & plasma, urine, and other sample types, by technology (polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, in situ hybridization, DNA sequencing & next-generation sequencing (NGS), DNA microarrays, and other technologies, by application (infectious disease diagnostics (hepatitis [hepatitis B, hepatitis C & other hepatitis diseases], HIV, CT/NG, HAI, HPV, tuberculosis, influenza, and other infectious diseases), oncology testing (breast cancer, colorectal cancer, lung cancer, prostate cancer, and other cancers), genetic testing and other applications), by end user (hospitals& clinics, diagnostic laboratories, and other end users), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the molecular diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the molecular diagnostics market. Competitive analysis of upcoming startups in the molecular diagnostics market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall molecular diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Increasing prevalence of infectious diseases and cancer globally, rising focus on R&D and growing funding in molecular diagnostics by healthcare-based companies, growing awareness regarding early disease diagnosis in developing countries, rising technological advancements in molecular diagnostics in recent years, and increasing use of PoC diagnostic tests in homecare settings and hospitals), opportunities (Growing significance of companion diagnostics in drug development process and increasing growth opportunities for molecular diagnostics companies in emerging economies), restraints (Unfavorable reimbursement scenario for diagnostic companies and high cost of molecular diagnostic instruments), and challenges (Changing regulatory landscape for IVD and molecular diagnostics in US and European Union, operational barriers and shortage of skills across major markets, and introduction of alternative technologies for disease detection and diagnosis) influencing the growth of the molecular diagnostics market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular diagnostics market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the molecular diagnostics market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular diagnostics market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Illumina, Inc. (US), bioMerieux (France), and Hologic, Inc. (US).
Show more
Product Code: MD 2521

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary interview participants
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation approach
      • 2.3.1.2 Approach 2: Presentation of companies and primary interviews
      • 2.3.1.3 Approach 3: Estimation of total molecular-based test for HIV in US
      • 2.3.1.4 Growth forecast
      • 2.3.1.5 CAGR projections
    • 2.3.2 TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5 MARKET SHARE ANALYSIS
  • 2.6 RESEARCH ASSUMPTIONS
    • 2.6.1 PARAMETRIC ASSUMPTIONS
    • 2.6.2 GROWTH RATE ASSUMPTIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 MOLECULAR DIAGNOSTICS MARKET OVERVIEW
  • 4.2 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029
  • 4.3 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2024 VS. 2029
  • 4.4 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024 VS. 2029
  • 4.5 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029
  • 4.6 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2024 VS. 2029
  • 4.7 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029
  • 4.8 MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing prevalence of infectious diseases and cancer
      • 5.2.1.2 Growing R&D funding
      • 5.2.1.3 Surge in technological advancements
      • 5.2.1.4 Rising use of point-of-care diagnostic tests
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Inadequate reimbursements
      • 5.2.2.2 High cost of molecular diagnostic instruments
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing significance of companion diagnostics
      • 5.2.3.2 Increasing growth opportunities in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Changing regulatory landscape
      • 5.2.4.2 Operational barriers and labor shortage
      • 5.2.4.3 Introduction of alternative technologies
  • 5.3 PRICING ANALYSIS
    • 5.3.1 INDICATIVE PRICING ANALYSIS
    • 5.3.2 AVERAGE SELLING PRICE, BY REGION
  • 5.4 PATENT ANALYSIS
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 TRADE ANALYSIS
  • 5.8 ECOSYSTEM ANALYSIS
    • 5.8.1 MOLECULAR DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF BUYERS
    • 5.9.4 BARGAINING POWER OF SUPPLIERS
    • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.10.2 NORTH AMERICA
      • 5.10.2.1 US
      • 5.10.2.2 Canada
    • 5.10.3 EUROPE
    • 5.10.4 ASIA PACIFIC
      • 5.10.4.1 China
      • 5.10.4.2 Japan
      • 5.10.4.3 India
    • 5.10.5 LATIN AMERICA
      • 5.10.5.1 Brazil
      • 5.10.5.2 Mexico
    • 5.10.6 MIDDLE EAST
    • 5.10.7 AFRICA
  • 5.11 TECHNOLOGY ANALYSIS
    • 5.11.1 KEY TECHNOLOGY
      • 5.11.1.1 Polymerase chain reaction
    • 5.11.2 COMPLEMENTARY TECHNOLOGY
      • 5.11.2.1 Microarrays
    • 5.11.3 ADJACENT TECHNOLOGY
      • 5.11.3.1 Next-generation sequencing
  • 5.12 KEY CONFERENCES AND EVENTS, 2024-2025
  • 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.14.2 BUYING CRITERIA
  • 5.15 INVESTMENT AND FUNDING SCENARIO
  • 5.16 CASE STUDY ANALYSIS
  • 5.17 IMPACT OF ARTIFICIAL INTELLIGENCE ON MOLECULAR DIAGNOSTICS MARKET

6 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
  • 6.2 REAGENTS & KITS
    • 6.2.1 INCREASING AWARENESS ABOUT EARLY DISEASE DETECTION AND PREVENTIVE HEALTHCARE TO PROPEL MARKET
  • 6.3 INSTRUMENTS
    • 6.3.1 RISING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST MARKET
  • 6.4 SERVICES & SOFTWARE
    • 6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE MARKET

7 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE

  • 7.1 INTRODUCTION
    • 7.1.1 KEY INDUSTRY INSIGHTS
  • 7.2 LAB TESTS
    • 7.2.1 INCREASING NEED FOR AUTOMATION AND EFFICIENT DISEASE TESTING TO DRIVE MARKET
  • 7.3 POC TESTS
    • 7.3.1 GROWING INVESTMENTS FROM PUBLIC HEALTH AGENCIES AND GOVERNMENT TO BOOST MARKET

8 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE

  • 8.1 INTRODUCTION
  • 8.2 BLOOD, SERUM, AND PLASMA
    • 8.2.1 INCREASING UTILIZATION IN GENETIC TESTING, INFECTIOUS DISEASE DIAGNOSIS, AND CANCER DIAGNOSTICS TO PROPEL MARKET
  • 8.3 URINE
    • 8.3.1 NEED FOR NON-INVASIVE AND EASY SAMPLE COLLECTION TECHNIQUE TO FUEL MARKET
  • 8.4 OTHER SAMPLE TYPES

9 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 9.1 INTRODUCTION
  • 9.2 KEY INDUSTRY INSIGHTS
  • 9.3 POLYMERASE CHAIN REACTION
    • 9.3.1 RISING USE IN PROTEOMICS AND GENOMICS TO AID GROWTH
  • 9.4 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
    • 9.4.1 NEED TO DEVELOP ANTIRETROVIRAL DRUGS AND PROMPT DIAGNOSIS TO STIMULATE GROWTH
  • 9.5 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
    • 9.5.1 GROWING SHIFT TOWARD MOLECULAR-TARGETED DRUGS AND THERAPIES TO DRIVE MARKET
  • 9.6 IN SITU HYBRIDIZATION
    • 9.6.1 RISING APPLICATIONS IN DIAGNOSING CHROMOSOMAL ABNORMALITIES, GENE MAPPING, AND INFERTILITY TREATMENT TO BOOST MARKET
  • 9.7 DNA MICROARRAYS
    • 9.7.1 SURGE IN ADVANCEMENTS IN DESIGN, DENSITY, AND DETECTION TECHNIQUES TO FUEL MARKET
  • 9.8 OTHER TECHNOLOGIES

10 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

  • 10.1 INTRODUCTION
  • 10.2 INFECTIOUS DISEASE DIAGNOSTICS
    • 10.2.1 HEPATITIS
      • 10.2.1.1 Hepatitis B
        • 10.2.1.1.1 Need for ongoing management and monitoring of virus to drive market
      • 10.2.1.2 Hepatitis C
        • 10.2.1.2.1 Favorable government initiatives to support growth
      • 10.2.1.3 Other hepatitis diseases
    • 10.2.2 HIV
      • 10.2.2.1 Increasing blood transfusions and blood donations to propel market
    • 10.2.3 CT/NG
      • 10.2.3.1 Growing development of novel assays to boost market
    • 10.2.4 HAI
      • 10.2.4.1 Booming geriatric population to aid growth
    • 10.2.5 HPV
      • 10.2.5.1 Rising cases of cervical cancer to augment growth
    • 10.2.6 TUBERCULOSIS
      • 10.2.6.1 Rising focus on reducing tuberculosis deaths to fuel market
    • 10.2.7 INFLUENZA
      • 10.2.7.1 Growing strains and subtypes to drive market
    • 10.2.8 OTHER INFECTIOUS DISEASES
  • 10.3 ONCOLOGY TESTING
    • 10.3.1 BREAST CANCER
      • 10.3.1.1 Increasing need to improve survival rates to support growth
    • 10.3.2 COLORECTAL CANCER
      • 10.3.2.1 Rising demand for biomarkers to fuel market
    • 10.3.3 LUNG CANCER
      • 10.3.3.1 Increasing use of predictive biomarkers to drive market
    • 10.3.4 PROSTATE CANCER
      • 10.3.4.1 Surge in advancements in genomic technologies to aid growth
    • 10.3.5 OTHER CANCER TYPES
  • 10.4 GENETIC TESTING
    • 10.4.1 GROWING IMPORTANCE IN DIAGNOSING AND MANAGING RARE GENETIC DISEASES TO PROPEL MARKET
  • 10.5 OTHER APPLICATIONS

11 MOLECULAR DIAGNOSTICS MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 DIAGNOSTIC LABORATORIES
    • 11.2.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR COST REDUCTION TO AID GROWTH
  • 11.3 HOSPITALS & CLINICS
    • 11.3.1 GROWING FOCUS ON HEALTHCARE SYSTEMS TO STIMULATE GROWTH
  • 11.4 OTHER END USERS

12 MOLECULAR DIAGNOSTICS MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 US
      • 12.2.1.1 Presence of advanced healthcare infrastructure and high healthcare expenditures to drive market
    • 12.2.2 CANADA
      • 12.2.2.1 Growing focus on genomic research to fuel market
  • 12.3 EUROPE
    • 12.3.1 GERMANY
      • 12.3.1.1 Robust healthcare spending and increasing per capita disposable income to propel market
    • 12.3.2 UK
      • 12.3.2.1 Increasing number of accredited clinical laboratories and hospital laboratories to fuel market
    • 12.3.3 FRANCE
      • 12.3.3.1 Rising R&D expenditure for product launches and development of new technologies to augment market
    • 12.3.4 ITALY
      • 12.3.4.1 Growing demographic shift toward elderly population to support market
    • 12.3.5 SPAIN
      • 12.3.5.1 Surge in demand for genetic and prenatal testing to aid growth
    • 12.3.6 RUSSIA
      • 12.3.6.1 Increasing access to quality healthcare to boost market
    • 12.3.7 SWITZERLAND
      • 12.3.7.1 Rising healthcare spending for new medications and therapies to drive market
    • 12.3.8 REST OF EUROPE
  • 12.4 ASIA PACIFIC
    • 12.4.1 CHINA
      • 12.4.1.1 Rapid economic growth to drive market
    • 12.4.2 JAPAN
      • 12.4.2.1 Universal healthcare reimbursement policy to support market
    • 12.4.3 INDIA
      • 12.4.3.1 Increasing penetration of medical insurance, hospital setups, and foreign direct investments to fuel market
    • 12.4.4 AUSTRALIA
      • 12.4.4.1 Rising technological advancements and automation to stimulate growth
    • 12.4.5 SOUTH KOREA
      • 12.4.5.1 Favorable government initiatives for promoting medical tourism to support growth
    • 12.4.6 REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    • 12.5.1 BRAZIL
      • 12.5.1.1 Need for accurate and detailed disease profiling to drive market
    • 12.5.2 MEXICO
      • 12.5.2.1 Booming medical tourism industry to aid growth
    • 12.5.3 REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 GROWING INVESTMENTS IN HEALTHCARE PROJECTS TO PROPEL MARKET
  • 12.7 GCC COUNTRIES
    • 12.7.1 RISING FOCUS ON ADVANCED HEALTH INFRASTRUCTURE TO DRIVE MARKET

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET
  • 13.3 REVENUE ANALYSIS
  • 13.4 MARKET SHARE ANALYSIS
    • 13.4.1 MOLECULAR DIAGNOSTICS MARKET RANKING ANALYSIS, BY TECHNOLOGY
      • 13.4.1.1 Polymerase chain reaction
      • 13.4.1.2 DNA sequencing and next-generation sequencing
      • 13.4.1.3 Isothermal nucleic acid amplification technology
      • 13.4.1.4 In situ hybridization
    • 13.4.2 MOLECULAR DIAGNOSTICS MARKET RANKING ANALYSIS, BY APPLICATION
      • 13.4.2.1 Infectious disease diagnostics
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 13.5.1 STARS
    • 13.5.2 EMERGING LEADERS
    • 13.5.3 PERVASIVE PLAYERS
    • 13.5.4 PARTICIPANTS
    • 13.5.5 COMPANY FOOTPRINT, KEY PLAYERS, 2023
      • 13.5.5.1 Company footprint
      • 13.5.5.2 Product footprint
      • 13.5.5.3 Application footprint
      • 13.5.5.4 Region footprint
  • 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 RESPONSIVE COMPANIES
    • 13.6.3 DYNAMIC COMPANIES
    • 13.6.4 STARTING BLOCKS
    • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 13.7 COMPANY VALUATION AND FINANCIAL METRICS
    • 13.7.1 FINANCIAL METRICS
    • 13.7.2 COMPANY VALUATION
  • 13.8 BRAND/PRODUCT COMPARISON
    • 13.8.1 DANAHER
    • 13.8.2 F. HOFFMANN-LA ROCHE LTD.
    • 13.8.3 ABBOTT
  • 13.9 COMPETITIVE SCENARIO
    • 13.9.1 PRODUCT LAUNCHES
    • 13.9.2 DEALS

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
    • 14.1.1 DANAHER
      • 14.1.1.1 Business overview
      • 14.1.1.2 Products offered
      • 14.1.1.3 Recent developments
        • 14.1.1.3.1 Product launches and approvals
        • 14.1.1.3.2 Deals
        • 14.1.1.3.3 Expansions
      • 14.1.1.4 MnM view
        • 14.1.1.4.1 Right to win
        • 14.1.1.4.2 Strategic choices
        • 14.1.1.4.3 Weaknesses and competitive threats
    • 14.1.2 F. HOFFMANN-LA ROCHE LTD.
      • 14.1.2.1 Business overview
      • 14.1.2.2 Products offered
      • 14.1.2.3 Recent developments
        • 14.1.2.3.1 Product launches and approvals
        • 14.1.2.3.2 Deals
      • 14.1.2.4 MnM view
        • 14.1.2.4.1 Right to win
        • 14.1.2.4.2 Strategic choices
        • 14.1.2.4.3 Weaknesses and competitive threats
    • 14.1.3 ILLUMINA, INC.
      • 14.1.3.1 Business overview
      • 14.1.3.2 Products offered
      • 14.1.3.3 Recent developments
        • 14.1.3.3.1 Product launches and approvals
        • 14.1.3.3.2 Deals
        • 14.1.3.3.3 Expansions
      • 14.1.3.4 MnM view
        • 14.1.3.4.1 Right to win
        • 14.1.3.4.2 Strategic choices
        • 14.1.3.4.3 Weaknesses and competitive threats
    • 14.1.4 HOLOGIC, INC.
      • 14.1.4.1 Business overview
      • 14.1.4.2 Products offered
      • 14.1.4.3 Recent developments
        • 14.1.4.3.1 Product launches and approvals
        • 14.1.4.3.2 Deals
      • 14.1.4.4 MnM view
        • 14.1.4.4.1 Right to win
        • 14.1.4.4.2 Strategic choices
        • 14.1.4.4.3 Weaknesses and competitive threats
    • 14.1.5 BIOMERIEUX
      • 14.1.5.1 Business overview
      • 14.1.5.2 Products offered
      • 14.1.5.3 Recent developments
        • 14.1.5.3.1 Product launches and approvals
        • 14.1.5.3.2 Deals
      • 14.1.5.4 MnM view
        • 14.1.5.4.1 Right to win
        • 14.1.5.4.2 Strategic choices
        • 14.1.5.4.3 Weaknesses and competitive threats
    • 14.1.6 ABBOTT
      • 14.1.6.1 Business overview
      • 14.1.6.2 Products offered
      • 14.1.6.3 Recent developments
        • 14.1.6.3.1 Product launches and approvals
    • 14.1.7 THERMO FISHER SCIENTIFIC INC.
      • 14.1.7.1 Business overview
      • 14.1.7.2 Products offered
      • 14.1.7.3 Recent developments
        • 14.1.7.3.1 Product launches and approvals
        • 14.1.7.3.2 Deals
    • 14.1.8 QIAGEN
      • 14.1.8.1 Business overview
      • 14.1.8.2 Products offered
      • 14.1.8.3 Recent developments
        • 14.1.8.3.1 Product launches and approvals
        • 14.1.8.3.2 Deals
        • 14.1.8.3.3 Expansions
    • 14.1.9 REVVITY
      • 14.1.9.1 Business overview
      • 14.1.9.2 Products offered
    • 14.1.10 MYRIAD GENETICS, INC.
      • 14.1.10.1 Business overview
      • 14.1.10.2 Products offered
      • 14.1.10.3 Recent developments
        • 14.1.10.3.1 Product launches and approvals
    • 14.1.11 SIEMENS HEALTHINEERS AG
      • 14.1.11.1 Business overview
      • 14.1.11.2 Products offered
      • 14.1.11.3 Recent developments
        • 14.1.11.3.1 Product launches and approvals
        • 14.1.11.3.2 Deals
        • 14.1.11.3.3 Expansions
  • 14.2 OTHER PLAYERS
    • 14.2.1 BECTON, DICKINSON AND COMPANY
    • 14.2.2 GRIFOLS, S.A.
    • 14.2.3 QUIDELORTHO CORPORATION
    • 14.2.4 DIASORIN S.P.A.
    • 14.2.5 EXACT SCIENCES CORPORATION
    • 14.2.6 GENETIC SIGNATURES
    • 14.2.7 AGILENT TECHNOLOGIES, INC.
    • 14.2.8 MDXHEALTH
    • 14.2.9 BIOCARTIS
    • 14.2.10 TBG DIAGNOSTICS LIMITED
    • 14.2.11 HTG MOLECULAR DIAGNOSTICS, INC.
    • 14.2.12 VELA DIAGNOSTICS
    • 14.2.13 AMOY DIAGNOSTICS CO., LTD.
    • 14.2.14 ELITECHGROUP
    • 14.2.15 MOLBIO DIAGNOSTICS PVT. LTD.
    • 14.2.16 GENEOMBIO TECHNOLOGIES
    • 14.2.17 SAVYON DIAGNOSTICS
    • 14.2.18 UNIOGEN OY

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS
Show more
Product Code: MD 2521

List of Tables

  • TABLE 1 INCLUSIONS AND EXCLUSIONS
  • TABLE 2 TYPES OF CANCER CASES WORLDWIDE, 2022 VS. 2045
  • TABLE 3 NUMBER OF CANCER PATIENTS WORLDWIDE, BY REGION, 2022 VS. 2035 VS. 2045
  • TABLE 4 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY PRODUCT, 2024
  • TABLE 5 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION, 2022-2024
  • TABLE 6 PATENT REGISTRATIONS, 2022
  • TABLE 7 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 8 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 9 MOLECULAR DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 CLASSIFICATION OF MEDICAL AND DIAGNOSTIC DEVICES IN EUROPE
  • TABLE 16 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
  • TABLE 17 MOLECULAR DIAGNOSTICS MARKET: KEY CONFERENCES AND EVENTS, 2024-2025
  • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
  • TABLE 19 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • TABLE 20 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 21 AVERAGE SELLING PRICE OF MOLECULAR DIAGNOSTIC PRODUCTS, 2024
  • TABLE 22 KEY REAGENTS AND KITS AVAILABLE WORLDWIDE
  • TABLE 23 MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 24 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 25 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 26 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 27 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 28 KEY INSTRUMENTS AVAILABLE WORLDWIDE
  • TABLE 29 MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 30 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY 2022-2029 (USD MILLION)
  • TABLE 31 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 32 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 33 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 34 KEY SOFTWARE SOLUTIONS AVAILABLE WORLDWIDE
  • TABLE 35 MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 36 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 37 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 38 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 39 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 40 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
  • TABLE 41 KEY LABORATORY TESTING INSTRUMENTS AVAILABLE WORLDWIDE
  • TABLE 42 MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 43 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 46 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LAB TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 47 KEY POC TESTING DEVICES AVAILABLE WORLDWIDE
  • TABLE 48 MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 49 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 50 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 53 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
  • TABLE 54 KEY BLOOD, SERUM, AND PLASMA SAMPLE TYPE-BASED PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 55 MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 56 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 57 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 58 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 59 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 60 KEY URINE SAMPLE TYPE-BASED PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 61 MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 62 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 63 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 64 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 65 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 66 KEY OTHER SAMPLE TYPE-BASED PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 67 MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 68 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 69 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 70 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 72 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 73 KEY POLYMERASE CHAIN REACTION INSTRUMENTS AVAILABLE WORLDWIDE
  • TABLE 74 MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 75 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 76 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 77 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 78 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 79 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY INSTRUMENTS AVAILABLE IN GLOBAL MARKET
  • TABLE 80 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 81 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 82 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 83 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 84 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 85 KEY NEXT-GENERATION SEQUENCING-BASED INSTRUMENTS AVAILABLE WORLDWIDE
  • TABLE 86 MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 87 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 88 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 89 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 90 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 91 KEY IN SITU HYBRIDIZATION PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 92 MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 93 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY 2022-2029 (USD MILLION)
  • TABLE 94 EUROPE: MOLECULAR DIAGNOSTICS MARKET IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 95 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 96 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 97 KEY MICROARRAY-BASED PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 98 MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 99 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 100 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 101 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 102 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 103 MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 104 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 105 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 106 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 107 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 108 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 109 KEY INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 110 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 111 MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 112 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 113 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 114 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 115 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 116 KEY HEPATITIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 117 MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 118 MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 119 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 120 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 122 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 123 NORTH AMERICA: TOTAL MOLECULAR DIAGNOSTICS-BASED HEPATITIS TEST COUNT, BY COUNTRY, 2022-2029
  • TABLE 124 MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 125 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 126 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 127 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 128 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 129 MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 130 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 131 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 132 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 133 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 134 MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 135 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 136 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 137 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 138 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 139 KEY HIV MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 140 MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 141 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 142 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 143 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 144 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 145 NORTH AMERICA: TOTAL MOLECULAR DIAGNOSTICS-BASED HIV TEST COUNT, BY COUNTRY, 2022-2029
  • TABLE 146 KEY CT/NG MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 147 MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 148 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 149 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 150 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 151 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR CT/NG, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 152 KEY HAI MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 153 MOLECULAR DIAGNOSTICS MARKET FOR HAI, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 154 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HAI, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 155 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HAI, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 156 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HAI, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 157 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HAI, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 158 KEY HPV MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 159 MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 160 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 161 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 162 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 163 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 164 KEY TUBERCULOSIS MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 165 MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 166 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 167 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 168 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 169 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 170 NORTH AMERICA: TOTAL MOLECULAR DIAGNOSTICS-BASED TUBERCULOSIS TEST COUNT, BY COUNTRY, 2022-2029
  • TABLE 171 KEY INFLUENZA MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 172 MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 173 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 174 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 175 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 176 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 177 GLOBAL CASES OF ACTIVE SYPHILIS IN 15-49-YEAR OLDS, 2016-2022 (THOUSANDS)
  • TABLE 178 KEY OTHER INFECTIOUS DISEASES MOLECULAR DIAGNOSTIC PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 179 MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 180 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 181 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 182 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 183 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 184 KEY ONCOLOGY TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 185 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 186 MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 187 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 188 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 189 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 190 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 191 BREAST CANCER INCIDENCE, BY REGION, 2022 VS. 2045
  • TABLE 192 MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 193 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 194 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 195 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 196 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 197 COLORECTAL CANCER INCIDENCE, BY REGION, 2022 VS. 2045
  • TABLE 198 MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 199 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 200 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 201 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 202 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 203 LUNG CANCER INCIDENCE, BY REGION, 2022 VS. 2045
  • TABLE 204 MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 205 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY 2022-2029 (USD MILLION)
  • TABLE 206 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 207 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 208 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 209 PROSTATE CANCER INCIDENCE, BY REGION, 2022 VS. 2045
  • TABLE 210 MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 211 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 212 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 213 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 214 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 215 GLOBAL INCIDENCE OF OTHER CANCER TYPES, 2022 VS. 2045
  • TABLE 216 MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 217 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 218 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 219 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 220 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER CANCER TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 221 KEY GENETIC TESTING PRODUCTS AVAILABLE WORLDWIDE
  • TABLE 222 MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 223 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 224 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 225 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 226 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 227 MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 228 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 229 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 230 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 231 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 232 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 233 MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 234 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 235 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 236 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 237 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 238 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 239 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 240 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 241 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 242 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 243 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 244 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 245 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 246 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 247 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 248 PROJECTED CANCER CASES, BY COUNTRY, 2022 VS. 2045
  • TABLE 249 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 250 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 251 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 252 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
  • TABLE 253 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 254 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 255 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 256 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 257 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 258 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 259 US: CANCER CASES AND MORTALITY, 2022 VS. 2045
  • TABLE 260 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 261 US: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
  • TABLE 262 US: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 263 US: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 264 US: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 265 US: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 266 US: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 267 US: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 268 CANADA: PROJECTED CANCER CASES, BY TYPE, 2022 VS. 2045
  • TABLE 269 CANADA: 5 MOST COMMON CANCER DEATHS
  • TABLE 270 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 271 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
  • TABLE 272 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 273 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 274 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 275 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 276 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 277 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 278 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 279 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 280 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
  • TABLE 281 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 282 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 283 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 284 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 285 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 286 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 287 GERMANY: PROJECTED CANCER CASES, BY TYPE, 2022 VS. 2045
  • TABLE 288 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 289 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
  • TABLE 290 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 291 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 292 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 293 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 294 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 295 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 296 UK: PROJECTED CANCER CASES, BY TYPE, 2022 VS. 2045
  • TABLE 297 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 298 UK: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
  • TABLE 299 UK: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 300 UK: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 301 UK: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 302 UK: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 303 UK: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 304 UK: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 305 FRANCE: PROJECTED CANCER CASES, BY TYPE, 2022 VS. 2045
  • TABLE 306 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 307 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
  • TABLE 308 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 309 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 310 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 311 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 312 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 313 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 314 ITALY: PROJECTED CANCER CASES, BY TYPE, 2022 VS. 2045
  • TABLE 315 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
  • TABLE 316 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022-2029 (USD MILLION)
  • TABLE 317 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 318 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 319 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 320 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 321 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 322 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 323 SPAIN: PROJECTED CANCER CASES, BY TYPE, 2022 VS. 2045
  • TABLE 324 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 325 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 326 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 327 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 328 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 329 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 330 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 331 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 332 RUSSIA: PROJECTED CANCER CASES, BY TYPE, 2022 VS. 2045
  • TABLE 333 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 334 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 335 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 336 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 337 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 338 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 339 RUSSIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 340 RUSSIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 341 SWITZERLAND: PROJECTED CANCER CASES, BY TYPE, 2022 VS. 2045
  • TABLE 342 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 343 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 344 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 345 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 346 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 347 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 348 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 349 SWITZERLAND: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 350 REST OF EUROPE: CANCER CASES, 2022 VS. 2045, BY COUNTRY
  • TABLE 351 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 352 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 353 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 354 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 355 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 356 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 357 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 358 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 359 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 360 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 361 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 362 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 363 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 364 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 365 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 366 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 367 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 368 CHINA: PROJECTED CANCER CASES, BY TYPE, 2022 VS. 2045
  • TABLE 369 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 370 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 371 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 372 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 373 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 374 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 375 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 376 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 377 JAPAN: PROJECTED CANCER CASES, BY TYPE, 2022 VS. 2045
  • TABLE 378 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 379 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 380 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 381 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 382 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 383 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 384 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 385 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 386 INDIA: PROJECTED CANCER CASES, BY TYPE, 2022 VS. 2045
  • TABLE 387 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 388 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 389 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 390 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 391 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 392 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 393 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 394 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 395 AUSTRALIA: PROJECTED CANCER CASES, BY TYPE, 2022 VS. 2045
  • TABLE 396 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 397 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 398 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 399 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 400 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 401 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 402 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 403 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 404 SOUTH KOREA: PROJECTED CANCER CASES, BY TYPE, 2022 VS. 2045
  • TABLE 405 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 406 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 407 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 408 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 409 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 410 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 411 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 412 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 413 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 414 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 415 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 416 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 417 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 418 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 419 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 420 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 421 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 422 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 423 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 424 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 425 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 426 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 427 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 428 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 429 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 430 BRAZIL: PROJECTED CANCER CASES, BY TYPE, 2022 VS. 2045
  • TABLE 431 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 432 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 433 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 434 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 435 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 436 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 437 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 438 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 439 MEXICO: PROJECTED CANCER CASES, BY TYPE, 2022 VS. 2045
  • TABLE 440 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 441 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 442 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 443 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 444 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 445 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 446 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 447 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 448 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 449 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 450 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 451 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 452 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 453 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 454 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 455 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 456 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 457 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 458 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 459 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 460 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 461 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 462 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 463 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 464 GCC COUNTRIES: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 465 GCC COUNTRIES: MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 466 GCC COUNTRIES: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 467 GCC COUNTRIES: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 468 GCC COUNTRIES: MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 469 GCC COUNTRIES: MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 470 GCC COUNTRIES: MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY TESTING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 471 GCC COUNTRIES: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 472 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
  • TABLE 473 MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 474 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR POLYMERASE CHAIN REACTION, BY KEY PLAYER, 2023
  • TABLE 475 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR DNA SEQUENCING AND NEXT-GENERATION SEQUENCING, BY KEY PLAYER, 2023
  • TABLE 476 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY KEY PLAYER, 2023
  • TABLE 477 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR IN SITU HYBRIDIZATION, BY KEY PLAYER, 2023
  • TABLE 478 GLOBAL MOLECULAR DIAGNOSTICS MARKET RANKING FOR INFECTIOUS DISEASE DIAGNOSTICS, BY KEY PLAYER, 2023
  • TABLE 479 MOLECULAR DIAGNOSTICS MARKET: PRODUCT FOOTPRINT
  • TABLE 480 MOLECULAR DIAGNOSTICS MARKET: APPLICATION FOOTPRINT
  • TABLE 481 MOLECULAR DIAGNOSTICS MARKET: REGION FOOTPRINT
  • TABLE 482 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 483 MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • TABLE 484 MOLECULAR DIAGNOSTICS MARKET: PRODUCT LAUNCHES, JANUARY 2021–MAY 2024
  • TABLE 485 MOLECULAR DIAGNOSTICS MARKET: DEALS, JANUARY 2021– MAY 2024
  • TABLE 486 DANAHER: COMPANY OVERVIEW
  • TABLE 487 DANAHER: PRODUCTS OFFERED
  • TABLE 488 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–MAY 2024
  • TABLE 489 DANAHER: DEALS, JANUARY 2021–MAY 2024
  • TABLE 490 DANAHER: EXPANSIONS, JANUARY 2021–MAY 2024
  • TABLE 491 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 492 F. HOFFMAN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 493 F. HOFFMAN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–MAY 2024
  • TABLE 494 F. HOFFMAN-LA ROCHE LTD.: DEALS, JANUARY 2021–MAY 2024
  • TABLE 495 ILUMINA, INC.: COMPANY OVERVIEW
  • TABLE 496 ILLUMINA, INC.: PRODUCTS OFFERED
  • TABLE 497 ILLUMINA, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–MAY 2024
  • TABLE 498 ILLUMINA, INC.: DEALS, JANUARY 2021–MAY 2024
  • TABLE 499 ILLUMINA, INC.: EXPANSIONS, JANUARY 2021–MAY 2024
  • TABLE 500 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 501 HOLOGIC, INC.: PRODUCTS OFFERED
  • TABLE 502 HOLOGIC, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–MAY 2024
  • TABLE 503 HOLOGIC, INC.: DEALS, JANUARY 2021–MAY 2024
  • TABLE 504 BIOMÉRIEUX: COMPANY OVERVIEW
  • TABLE 505 BIOMÉRIEUX: PRODUCTS OFFERED
  • TABLE 506 BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–MAY 2024
  • TABLE 507 BIOMÉRIEUX: DEALS, JANUARY 2021–MAY 2024
  • TABLE 508 ABBOTT: COMPANY OVERVIEW
  • TABLE 509 ABBOTT: PRODUCTS OFFERED
  • TABLE 510 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–MAY 2024
  • TABLE 511 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 512 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 513 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–MAY 2024
  • TABLE 514 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–MAY 2024
  • TABLE 515 QIAGEN: COMPANY OVERVIEW
  • TABLE 516 QIAGEN: PRODUCTS OFFERED
  • TABLE 517 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–MAY 2024
  • TABLE 518 QIAGEN: DEALS, JANUARY 2021–MAY 2024
  • TABLE 519 QIAGEN: EXPANSIONS, JANUARY 2021–MAY 2024
  • TABLE 520 REVVITY: COMPANY OVERVIEW
  • TABLE 521 REVVITY: PRODUCTS OFFERED
  • TABLE 522 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
  • TABLE 523 MYRIAD GENETICS, INC.: PRODUCTS OFFERED
  • TABLE 524 MYRIAD GENETICS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-MAY 2024
  • TABLE 525 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 526 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 527 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–MAY 2024
  • TABLE 528 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021–MAY 2024
  • TABLE 529 SIEMENS HEALTHINEERS AG: EXPANSIONS
  • TABLE 530 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 531 GRIFOLS, S.A.: COMPANY OVERVIEW
  • TABLE 532 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 533 DIASORIN S.P.A.: COMPANY OVERVIEW
  • TABLE 534 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW
  • TABLE 535 GENETIC SIGNATURES: COMPANY OVERVIEW
  • TABLE 536 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 537 MDXHEALTH: COMPANY OVERVIEW
  • TABLE 538 BIOCARTIS: COMPANY OVERVIEW
  • TABLE 539 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
  • TABLE 540 HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY OVERVIEW
  • TABLE 541 VELA DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 542 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
  • TABLE 543 ELITECHGROUP: COMPANY OVERVIEW
  • TABLE 544 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW
  • TABLE 545 GENEOMBIO TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 546 SAVYON DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 547 UNIOGEN OY: COMPANY OVERVIEW "

List of Figures

  • FIGURE 1 MOLECULAR DIAGNOSTICS MARKET SEGMENTATION AND GEOGRAPHICAL SPREAD
  • FIGURE 2 MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 7 MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • FIGURE 8 DATA TRIANGULATION
  • FIGURE 9 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 10 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 11 MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND CANCER TO DRIVE MARKET
  • FIGURE 17 REAGENTS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 18 LAB TESTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 19 BLOOD, SERUM, AND PLASMA SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 20 POLYMERASE CHAIN REACTION SEGMENT TO SHOWCASE LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 21 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO DISPLAY LARGEST MARKET SHARE DURING FORECAST PERIOD
  • FIGURE 22 DIAGNOSTIC LABORATORIES SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2029
  • FIGURE 23 NORTH AMERICAN MARKET TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD
  • FIGURE 24 MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 AVERAGE SELLING PRICE OF PANELS IN US, BY KEY BRAND, 2024
  • FIGURE 26 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES, JANUARY 2014-DECEMBER 2023
  • FIGURE 27 VALUE CHAIN ANALYSIS OF MOLECULAR DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • FIGURE 28 MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 29 MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 30 REVENUE SHIFT IN MOLECULAR DIAGNOSTICS MARKET
  • FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
  • FIGURE 32 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • FIGURE 33 MOLECULAR DIAGNOSTICS MARKET: INVESTMENT AND FUNDING SCENARIO
  • FIGURE 34 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR FOR IN VITRO DIAGNOSTICS IN INDIA
  • FIGURE 35 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 36 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET, 2021-2023
  • FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN MOLECULAR DIAGNOSTICS MARKET, 2023
  • FIGURE 39 MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 40 MOLECULAR DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 41 MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 42 EV/EBITDA OF KEY VENDORS
  • FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 44 MOLECULAR DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 45 DANAHER: COMPANY SNAPSHOT (2023)
  • FIGURE 46 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 47 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 48 HOLOGIC, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 49 BIOMERIEUX: COMPANY SNAPSHOT (2023)
  • FIGURE 50 ABBOTT: COMPANY SNAPSHOT (2023)
  • FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 52 QIAGEN: COMPANY SNAPSHOT (2023)
  • FIGURE 53 REVVITY: COMPANY SNAPSHOT (2023)
  • FIGURE 54 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 55 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!